Johnson & Johnson

$ 138.61 0.4 (0.29%)
On watch
Volume: 6,830,097 Avg Vol (1m): 5,973,505
Market Cap $: 368.02 Bil Enterprise Value $: 382.05 Bil
P/E (TTM): 25.67 P/B: 6.35
Earnings Power Value 44.98
Net Current Asset Value -18.19
Tangible Book -7.19
Projected FCF 75.87
Median P/S Value 111.65
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.52
Cash-To-Debt ranked lower than
65.77% of 859 companies
in the Drug Manufacturers - Major industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
JNJ: 0.52
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.15, Med: 1.22, Max: 6.28
Current: 0.52
0.15
6.28
Equity-to-Asset 0.39
Equity-to-Asset ranked lower than
78.17% of 788 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
JNJ: 0.39
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.38, Med: 0.54, Max: 0.67
Current: 0.39
0.38
0.67
Debt-to-Equity 0.50
Debt-to-Equity ranked lower than
63.26% of 596 companies
in the Drug Manufacturers - Major industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
JNJ: 0.5
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.06, Med: 0.26, Max: 0.58
Current: 0.5
0.06
0.58
Debt-to-EBITDA 1.19
Debt-to-EBITDA ranked higher than
61.82% of 495 companies
in the Drug Manufacturers - Major industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
JNJ: 1.19
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.75, Med: 0.9, Max: 1.43
Current: 1.19
0.75
1.43
Interest Coverage 22.12
Interest Coverage ranked lower than
62.65% of 648 companies
in the Drug Manufacturers - Major industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
JNJ: 22.12
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 19.8, Med: 31.28, Max: 39.32
Current: 22.12
19.8
39.32
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.46
DISTRESS
GREY
SAFE
Beneish M-Score -2.70
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 21.53%
WACC 6.07%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 22.99
Operating Margin ranked higher than
86.77% of 801 companies
in the Drug Manufacturers - Major industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
JNJ: 22.99
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 23.61, Med: 25.78, Max: 29.02
Current: 22.99
23.61
29.02
Net Margin % 17.99
Net Margin ranked lower than
63.22% of 802 companies
in the Drug Manufacturers - Major industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
JNJ: 17.99
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 1.7, Med: 19.61, Max: 23.01
Current: 17.99
1.7
23.01
ROE % 23.72
ROE ranked lower than
60.58% of 832 companies
in the Drug Manufacturers - Major industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
JNJ: 23.72
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 1.99, Med: 22.29, Max: 26.35
Current: 23.72
1.99
26.35
ROA % 9.52
ROA ranked lower than
59.59% of 871 companies
in the Drug Manufacturers - Major industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
JNJ: 9.52
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 0.87, Med: 11.29, Max: 13.66
Current: 9.52
0.87
13.66
ROC (Joel Greenblatt) % 96.50
ROC (Joel Greenblatt) ranked higher than
96.02% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
JNJ: 96.5
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 65.66, Med: 97.67, Max: 119.25
Current: 96.5
65.66
119.25
3-Year Total Revenue Growth Rate 5.20
3-Year Revenue Growth Rate ranked lower than
62.70% of 689 companies
in the Drug Manufacturers - Major industry.
Industry Max: 291.9, Med: 5.8, Min: -100
JNJ: 6.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 1.3, Med: 7.4, Max: 14.8
Current: 6.3
1.3
14.8
3-Year Total EBITDA Growth Rate 3.30
3-Year EBITDA Growth Rate ranked lower than
65.34% of 704 companies
in the Drug Manufacturers - Major industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
JNJ: 4.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -6.6, Med: 9.7, Max: 19.3
Current: 4.4
-6.6
19.3
3-Year EPS w/o NRI Growth Rate 0.80
3-Year EPS w/o NRI Growth Rate ranked lower than
94.42% of 663 companies
in the Drug Manufacturers - Major industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
JNJ: 0.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -56.5, Med: 10.9, Max: 34.2
Current: 0.8
-56.5
34.2

» JNJ's 30-Y Financials

Financials (Next Earnings Date: 2019-07-16)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:JNJ

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare XSWX:RO NYSE:PFE NYSE:MRK XSWX:NOVN NYSE:ABBV NYSE:LLY NAS:AMGN XPAR:SAN LSE:GSK LSE:AZN NAS:GILD NYSE:BMY NAS:CELG XTER:BAYN NAS:BIIB TSE:4519 TSE:4568 TSE:4503 TSE:4578 XMAD:GRF.P
Traded in other countries JNJB34.Brazil 0R34.UK
Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. Close to half of total revenue is generated within the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 25.67
PE Ratio ranked lower than
97.67% of 557 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
JNJ: 25.67
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 10.5, Med: 18.73, Max: 377.85
Current: 25.67
10.5
377.85
Forward PE Ratio 16.10
Forward P/E ranked higher than
69.37% of 111 companies
in the Drug Manufacturers - Major industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
JNJ: 16.1
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 25.67
PE without NRI ranked lower than
97.48% of 556 companies
in the Drug Manufacturers - Major industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
JNJ: 25.67
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 10.5, Med: 18.73, Max: 377.85
Current: 25.67
10.5
377.85
Price-to-Owner-Earnings 21.82
Price-to-Owner-Earnings ranked higher than
72.53% of 324 companies
in the Drug Manufacturers - Major industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
JNJ: 21.82
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 10.19, Med: 17.92, Max: 24.56
Current: 21.82
10.19
24.56
PB Ratio 6.35
PB Ratio ranked lower than
78.51% of 819 companies
in the Drug Manufacturers - Major industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
JNJ: 6.35
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.68, Med: 3.72, Max: 6.57
Current: 6.35
2.68
6.57
PS Ratio 4.62
PS Ratio ranked lower than
61.94% of 775 companies
in the Drug Manufacturers - Major industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
JNJ: 4.62
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.16, Med: 3.72, Max: 5.29
Current: 4.62
2.16
5.29
Price-to-Free-Cash-Flow 20.42
Price-to-Free-Cash-Flow ranked higher than
68.79% of 298 companies
in the Drug Manufacturers - Major industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
JNJ: 20.42
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 10.29, Med: 18.45, Max: 24.34
Current: 20.42
10.29
24.34
Price-to-Operating-Cash-Flow 17.03
Price-to-Operating-Cash-Flow ranked higher than
64.80% of 392 companies
in the Drug Manufacturers - Major industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
JNJ: 17.03
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 8.99, Med: 15, Max: 19.52
Current: 17.03
8.99
19.52
EV-to-EBIT 21.48
EV-to-EBIT ranked lower than
54.02% of 572 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
JNJ: 21.48
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 7.8, Med: 14.1, Max: 22.6
Current: 21.48
7.8
22.6
EV-to-EBITDA 15.45
EV-to-EBITDA ranked higher than
55.11% of 597 companies
in the Drug Manufacturers - Major industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
JNJ: 15.45
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 6.7, Med: 11.6, Max: 17.3
Current: 15.45
6.7
17.3
EV-to-Revenue 4.68
EV-to-Revenue ranked lower than
60.50% of 795 companies
in the Drug Manufacturers - Major industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
JNJ: 4.68
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.1, Med: 3.5, Max: 5.5
Current: 4.68
2.1
5.5
PEG Ratio 5.35
PEG Ratio ranked lower than
97.79% of 317 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
JNJ: 5.35
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 1.17, Med: 2.4, Max: 63.74
Current: 5.35
1.17
63.74
Shiller PE Ratio 28.50
Shiller PE Ratio ranked higher than
58.33% of 252 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
JNJ: 28.5
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 15.52, Med: 21.28, Max: 31.62
Current: 28.5
15.52
31.62
Current Ratio 1.44
Current Ratio ranked lower than
66.32% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
JNJ: 1.44
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.2, Med: 1.91, Max: 3.08
Current: 1.44
1.2
3.08
Quick Ratio 1.13
Quick Ratio ranked lower than
63.04% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
JNJ: 1.13
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.94, Med: 1.47, Max: 2.68
Current: 1.13
0.94
2.68
Days Inventory 119.06
Days Inventory ranked lower than
51.13% of 755 companies
in the Drug Manufacturers - Major industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
JNJ: 119.06
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 101.23, Med: 119.14, Max: 137.6
Current: 119.06
101.23
137.6
Days Sales Outstanding 63.14
Days Sales Outstanding ranked higher than
65.97% of 770 companies
in the Drug Manufacturers - Major industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
JNJ: 63.14
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 53.94, Med: 59.4, Max: 64.41
Current: 63.14
53.94
64.41
Days Payable 93.27
Days Payable ranked higher than
55.15% of 758 companies
in the Drug Manufacturers - Major industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
JNJ: 93.27
Ranked among companies with meaningful Days Payable only.
N/A

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 2.60
Trailing Dividend Yield ranked higher than
72.34% of 752 companies
in the Drug Manufacturers - Major industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
JNJ: 2.6
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 2.25, Med: 2.84, Max: 3.84
Current: 2.6
2.25
3.84
Dividend Payout Ratio 0.67
Dividend Payout Ratio ranked lower than
99.16% of 477 companies
in the Drug Manufacturers - Major industry.
Industry Max: 68, Med: 0.3, Min: 0.02
JNJ: 0.67
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.44, Med: 0.54, Max: 7.06
Current: 0.67
0.44
7.06
3-Year Dividend Growth Rate (Per Share) 6.30
3-Year Dividend Growth Rate ranked lower than
51.51% of 299 companies
in the Drug Manufacturers - Major industry.
Industry Max: 114, Med: 7.4, Min: -100
JNJ: 6.3
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
3-Year Dividend Growth Rate range over the past 10 years
Min: 6.3, Med: 13.3, Max: 17.1
Current: 6.3
6.3
17.1
Forward Dividend Yield % 2.74
Forward Dividend Yield ranked higher than
70.79% of 719 companies
in the Drug Manufacturers - Major industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
JNJ: 2.74
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 3.55
Yield-on-Cost (5y) ranked higher than
71.95% of 745 companies
in the Drug Manufacturers - Major industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
JNJ: 3.55
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 3.07, Med: 3.87, Max: 5.24
Current: 3.55
3.07
5.24
3-Year Share Buyback Rate 0.90
3-Year Share Buyback Rate ranked higher than
94.92% of 571 companies
in the Drug Manufacturers - Major industry.
Industry Max: 100, Med: -5.3, Min: -815
JNJ: 0.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -4.3, Med: 0.4, Max: 2.4
Current: 0.9
-4.3
2.4

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.82
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
57.49% of 374 companies
in the Drug Manufacturers - Major industry.
Industry Max: 209, Med: 2.11, Min: 0.05
JNJ: 1.82
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.85, Med: 1.65, Max: 3.51
Current: 1.82
0.85
3.51
Price-to-Median-PS-Value 1.24
Price-to-Median-PS-Value ranked lower than
73.35% of 743 companies
in the Drug Manufacturers - Major industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
JNJ: 1.24
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.47, Med: 0.94, Max: 1.63
Current: 1.24
0.47
1.63
Earnings Yield (Joel Greenblatt) % 4.66
Earnings Yield (Greenblatt) ranked higher than
64.36% of 867 companies
in the Drug Manufacturers - Major industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
JNJ: 4.66
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 4.4, Med: 7.1, Max: 12.9
Current: 4.66
4.4
12.9
Forward Rate of Return (Yacktman) % 7.64
Forward Rate of Return ranked higher than
51.07% of 421 companies
in the Drug Manufacturers - Major industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
JNJ: 7.64
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 2, Med: 11.9, Max: 17.4
Current: 7.64
2
17.4

More Statistics

Revenue (TTM) (Mil) $ 81,593
EPS (TTM) $ 5.4
Beta 0.68
Volatility % 18.37
52-Week Range $ 118.62 - 148.99
Shares Outstanding (Mil) 2,655.06

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N